The Filings Report

Biogen Inc. Common Stock

BIIBNasdaqCIK 875045Healthcare / Biotechnologyfiscal year ends December74 quarters since 2008

Revenue, Q3 FY2026
$2.8B
+10.6% on Q3 FY2025
Net income
−$21M
−104.4% on Q3 FY2025
Free cash flow
$600M
−51.0% on Q3 FY2025
Diluted EPS
$-0.14
−104.4% on Q3 FY2025
Revenue, TTM
$10.3B
trailing four quarters
Net margin, TTM
3.4%
net income $348M
Free cash flow, TTM
$2.1B
$2.2B less $176M capex
Cash and equivalents
—
long-term debt $7.3B, Sep 30, 2026
Shares, 12-month change
+0.8%
148M shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$37.5B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 28, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Biogen Inc. Common Stock reported revenue of $2.8B, +10.6% on Q3 FY2025, and net loss of $21M (−104.4%). Free cash flow, operating cash flow less capital expenditures, was $600M ($641M less $40M). Diluted earnings per share were $-0.14.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 28, 2026.

Revenue and net incomeRevenueNet income
−$1B$0$1B$2B$3BQ4'22, Revenue: $2.5BQ4'22, Net income: $550MQ4'22Q1'23, Revenue: $2.5BQ1'23, Net income: $388MQ1'23Q2'23, Revenue: $2.5BQ2'23, Net income: $592MQ2'23Q3'23, Revenue: $2.5BQ3'23, Net income: −$68MQ3'23Q4'23, Revenue: $2.4BQ4'23, Net income: $250MQ4'23Q1'24, Revenue: $2.3BQ1'24, Net income: $393MQ1'24Q2'24, Revenue: $2.5BQ2'24, Net income: $584MQ2'24Q3'24, Revenue: $2.5BQ3'24, Net income: $389MQ3'24Q4'24, Revenue: $2.5BQ4'24, Net income: $267MQ4'24Q1'25, Revenue: $2.4BQ1'25, Net income: $241MQ1'25Q2'25, Revenue: $2.6BQ2'25, Net income: $635MQ2'25Q3'25, Revenue: $2.5BQ3'25, Net income: $467MQ3'25Q4'25, Revenue: $2.3BQ4'25, Net income: −$49MQ4'25Q1'26, Revenue: $2.5BQ1'26, Net income: $320MQ1'26Q2'26, Revenue: $2.7BQ2'26, Net income: $98MQ2'26Q3'26, Revenue: $2.8BQ3'26, Net income: −$21MQ3'26−$1B$0$1B$2B$3BQ4'22, Revenue: $2.5BQ4'22, Net income: $550MQ1'23, Revenue: $2.5BQ1'23, Net income: $388MQ1'23Q2'23, Revenue: $2.5BQ2'23, Net income: $592MQ3'23, Revenue: $2.5BQ3'23, Net income: −$68MQ3'23Q4'23, Revenue: $2.4BQ4'23, Net income: $250MQ1'24, Revenue: $2.3BQ1'24, Net income: $393MQ1'24Q2'24, Revenue: $2.5BQ2'24, Net income: $584MQ3'24, Revenue: $2.5BQ3'24, Net income: $389MQ3'24Q4'24, Revenue: $2.5BQ4'24, Net income: $267MQ1'25, Revenue: $2.4BQ1'25, Net income: $241MQ1'25Q2'25, Revenue: $2.6BQ2'25, Net income: $635MQ3'25, Revenue: $2.5BQ3'25, Net income: $467MQ3'25Q4'25, Revenue: $2.3BQ4'25, Net income: −$49MQ1'26, Revenue: $2.5BQ1'26, Net income: $320MQ1'26Q2'26, Revenue: $2.7BQ2'26, Net income: $98MQ3'26, Revenue: $2.8BQ3'26, Net income: −$21MQ3'26

Net income losses drawn in red.

Free cash flow
−$500M$0$500M$1.0B$1.5BQ4'22, Free cash flow: −$261MQ4'22Q1'23, Free cash flow: $389MQ1'23Q2'23, Free cash flow: $416MQ2'23Q3'23, Free cash flow: $518MQ3'23Q4'23, Free cash flow: −$53MQ4'23Q1'24, Free cash flow: $507MQ1'24Q2'24, Free cash flow: $592MQ2'24Q3'24, Free cash flow: $901MQ3'24Q4'24, Free cash flow: $722MQ4'24Q1'25, Free cash flow: $222MQ1'25Q2'25, Free cash flow: $134MQ2'25Q3'25, Free cash flow: $1.2BQ3'25Q4'25, Free cash flow: $468MQ4'25Q1'26, Free cash flow: $594MQ1'26Q2'26, Free cash flow: $408MQ2'26Q3'26, Free cash flow: $600MQ3'26−$500M$0$500M$1.0B$1.5BQ4'22, Free cash flow: −$261MQ1'23, Free cash flow: $389MQ1'23Q2'23, Free cash flow: $416MQ3'23, Free cash flow: $518MQ3'23Q4'23, Free cash flow: −$53MQ1'24, Free cash flow: $507MQ1'24Q2'24, Free cash flow: $592MQ3'24, Free cash flow: $901MQ3'24Q4'24, Free cash flow: $722MQ1'25, Free cash flow: $222MQ1'25Q2'25, Free cash flow: $134MQ3'25, Free cash flow: $1.2BQ3'25Q4'25, Free cash flow: $468MQ1'26, Free cash flow: $594MQ1'26Q2'26, Free cash flow: $408MQ3'26, Free cash flow: $600MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$2B$4B$6B$8BQ4'22, Long-term debt: $6.3BQ4'22Q1'23, Long-term debt: $6.3BQ1'23Q2'23, Long-term debt: $6.3BQ2'23Q3'23, Long-term debt: $6.8BQ3'23Q4'23, Long-term debt: $6.8BQ4'23Q1'24, Long-term debt: $6.3BQ1'24Q2'24, Long-term debt: $6.3BQ2'24Q3'24, Long-term debt: $4.5BQ3'24Q4'24, Long-term debt: $4.5BQ4'24Q1'25, Long-term debt: $4.5BQ1'25Q2'25, Long-term debt: $6.3BQ2'25Q3'25, Long-term debt: $6.3BQ3'25Q4'25, Long-term debt: $6.3BQ4'25Q1'26, Long-term debt: $6.3BQ1'26Q2'26, Long-term debt: $7.3BQ2'26Q3'26, Long-term debt: $7.3BQ3'26$0$2B$4B$6B$8BQ4'22, Long-term debt: $6.3BQ1'23, Long-term debt: $6.3BQ1'23Q2'23, Long-term debt: $6.3BQ3'23, Long-term debt: $6.8BQ3'23Q4'23, Long-term debt: $6.8BQ1'24, Long-term debt: $6.3BQ1'24Q2'24, Long-term debt: $6.3BQ3'24, Long-term debt: $4.5BQ3'24Q4'24, Long-term debt: $4.5BQ1'25, Long-term debt: $4.5BQ1'25Q2'25, Long-term debt: $6.3BQ3'25, Long-term debt: $6.3BQ3'25Q4'25, Long-term debt: $6.3BQ1'26, Long-term debt: $6.3BQ1'26Q2'26, Long-term debt: $7.3BQ3'26, Long-term debt: $7.3BQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 28, 2026.

Biogen Inc. Common Stock income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 28, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 6, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 12, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue2,8042,7362,4782,2792,5352,6462,4312,455+10.6%
Cost of revenue748777661496674605629584+11.0%
Gross profit—————————
Research and development—————————
Selling, general and administrative752710607683595584573680+26.4%
Operating income—————————
Other income (expense)113(1)(327)1723(339)−32.5%
Pretax income(9)132378(56)557744311292−101.6%
Income tax123558(7)911097125−87.2%
Net income(21)98320(49)467635241267−104.4%
Diluted EPS ($)(0.14)0.662.15—3.174.331.64—−104.4%
Diluted shares (millions)148149148—147147147——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 28, 2026.

Biogen Inc. Common Stock balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 28, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 6, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 12, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents—————————
Short-term investments0090080798——0−100.0%
Total current assets7,5847,3069,1908,9748,9377,9687,6267,457−15.1%
Total assets32,05432,08729,48329,44029,20828,33028,03328,049+9.7%
Total current liabilities3,8983,9172,9993,3493,2903,1845,2975,529+18.5%
Long-term debt7,2927,2906,2896,2876,2856,2844,5494,547+16.0%
Total liabilities13,13213,23910,83111,18311,00010,69611,05411,333+19.4%
Stockholders’ equity—————————
Shares outstanding (millions)148148148147147147147146—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 28, 2026.

Biogen Inc. Common Stock cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 28, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 6, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 12, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow6414496465121,273161259761−49.6%
Capital expenditures4041514446273739−12.6%
Free cash flow (CFO − capex)6004085944681,226134222722−51.0%
Depreciation and amortization241236204200202194183184+19.2%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 6, 2026.

Income statement

Biogen Inc. Common Stock income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 6, 2026FY2024ended Dec 31, 2024filed Feb 12, 2025FY2023ended Dec 31, 2023filed Feb 14, 2024FY2022ended Dec 31, 2022filed Feb 15, 2023FY2021ended Dec 31, 2021filed Feb 3, 2022FY2020ended Dec 31, 2020filed Feb 3, 2021FY2019ended Dec 31, 2019filed Feb 6, 2020FY2018ended Dec 31, 2018filed Feb 6, 2019FY2017ended Dec 31, 2017filed Feb 1, 2018FY2016ended Dec 31, 2016filed Feb 2, 2017FY2015ended Dec 31, 2015filed Feb 3, 2016FY2014ended Dec 31, 2014filed Feb 4, 2015FY2013ended Dec 31, 2013filed Feb 6, 2014FY2012ended Dec 31, 2012filed Feb 5, 2013FY2011ended Dec 31, 2011filed Feb 3, 2012FY2010ended Dec 31, 2010filed Feb 4, 2011FY2009ended Dec 31, 2009filed Feb 9, 2010FY2008ended Dec 31, 2008filed Jul 17, 2009FY2007ended Dec 31, 2007filed Jul 17, 2009
Revenue9,8919,6769,83610,17310,98213,44514,37813,45312,27411,44910,7649,7036,9325,5165,0494,7164,3774,0983,172
Cost of revenue2,4042,3102,5332,2782,1101,8051,9551,8161,6301,479———545467400382402335
Gross profit—————11,63912,42311,63710,6449,9709,5238,5326,0754,9714,5824,3163,995——
Research and development—————————————1,3351,2201,2491,2831,072925
Selling, general and administrative2,4342,4042,5502,4042,6742,5052,3752,1061,9341,9472,1132,2321,7121,2771,0561,032911925776
Operating income————2,8414,5507,0435,8895,3465,1524,8913,9722,5161,8561,7251,2491,2951,214780
Other income (expense)(306)(344)(315)108(1,095)4978311(217)(219)(124)(26)(35)(1)(13)(19)37(58)72
Pretax income1,5571,9061,2973,5921,7455,0487,1265,9005,1294,9334,7673,9472,4811,8551,7111,2301,3331,156852
Income tax264274135633539921,1581,4262,4591,2371,162990601471445331356366272
Net income1,2931,6321,1613,0471,5564,0015,8894,4312,5393,7033,5472,9351,8621,3801,2341,005970783638
Diluted EPS ($)8.7911.187.9720.8710.4024.8031.4221.5811.9216.9315.3412.377.815.765.043.943.352.651.99
Diluted shares (millions)147146146146150161187205213219231237238240245255289295320

Balance sheet

Biogen Inc. Common Stock balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 6, 2026FY2024ended Dec 31, 2024filed Feb 12, 2025FY2023ended Dec 31, 2023filed Feb 14, 2024FY2022ended Dec 31, 2022filed Feb 15, 2023FY2021ended Dec 31, 2021filed Feb 3, 2022FY2020ended Dec 31, 2020filed Feb 3, 2021FY2019ended Dec 31, 2019filed Feb 6, 2020FY2018ended Dec 31, 2018filed Feb 6, 2019FY2017ended Dec 31, 2017filed Feb 1, 2018FY2016ended Dec 31, 2016filed Feb 2, 2017FY2015ended Dec 31, 2015filed Feb 3, 2016FY2014ended Dec 31, 2014filed Feb 4, 2015FY2013ended Dec 31, 2013filed Feb 6, 2014FY2012ended Dec 31, 2012filed Feb 5, 2013FY2011ended Dec 31, 2011filed Feb 3, 2012FY2010ended Dec 31, 2010filed Feb 4, 2011FY2009ended Dec 31, 2009filed Feb 9, 2010FY2008ended Dec 31, 2008filed Jul 17, 2009FY2007ended Dec 31, 2007filed Jul 17, 2009
Cash and equivalents——————2,9141,2251,5742,3271,3081,205603571515760582622660
Short-term investments807001,4741,5411,2791,5622,3132,115————1,1351,176448682720—
Total current assets8,9747,4576,8599,7917,8576,8878,3827,6417,8738,7326,7004,5353,1853,2442,9752,5402,4812,458—
Total assets29,44028,04926,84524,55423,87724,61927,23425,28923,65322,87719,50514,31511,86310,1309,0508,0928,5528,479—
Total current liabilities3,3495,5293,4343,2734,2983,7424,8643,2953,3683,4202,5782,2181,7581,6579131,050715923—
Long-term debt6,2874,5476,7886,2816,2747,4264,4595,9375,9356,5136,5225805926871,0241,035———
Total liabilities11,18311,33312,04511,16612,91813,93313,89512,25711,05510,74810,1303,5013,2423,1662,6232,6432,2902,645—
Stockholders’ equity——14,79913,39810,89610,70013,34313,04012,61312,1409,37310,8098,6206,9626,4255,3976,2225,806—
Shares outstanding (millions)147146145144147152174197212216219235236236239241270——

Cash flow statement

Biogen Inc. Common Stock cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 6, 2026FY2024ended Dec 31, 2024filed Feb 12, 2025FY2023ended Dec 31, 2023filed Feb 14, 2024FY2022ended Dec 31, 2022filed Feb 15, 2023FY2021ended Dec 31, 2021filed Feb 3, 2022FY2020ended Dec 31, 2020filed Feb 3, 2021FY2019ended Dec 31, 2019filed Feb 6, 2020FY2018ended Dec 31, 2018filed Feb 6, 2019FY2017ended Dec 31, 2017filed Feb 1, 2018FY2016ended Dec 31, 2016filed Feb 2, 2017FY2015ended Dec 31, 2015filed Feb 3, 2016FY2014ended Dec 31, 2014filed Feb 4, 2015FY2013ended Dec 31, 2013filed Feb 6, 2014FY2012ended Dec 31, 2012filed Feb 5, 2013FY2011ended Dec 31, 2011filed Feb 3, 2012FY2010ended Dec 31, 2010filed Feb 4, 2011FY2009ended Dec 31, 2009filed Feb 9, 2010FY2008ended Dec 31, 2008filed Jul 17, 2009FY2007ended Dec 31, 2007filed Jul 17, 2009
Operating cash flow2,2052,8761,5471,3843,6404,2307,0796,1884,5514,5873,9192,9422,3451,8801,7281,6251,0751,5621,019
Capital expenditures154154277240258425515771867616643288246255208173166276284
Free cash flow (CFO − capex)2,0512,7221,2701,1443,3823,8056,5645,4173,6843,9713,2762,6542,0991,6251,5201,4529091,286735
Depreciation and amortization7806734955184884574656511,081683600688532366359356428462380
Share repurchases—007501,8006,6795,8684,3531,3651,0005,0008874009854982,0787517392,991
Dividends paid———————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$240K
2 sales by 1 insider; officers and directors $240K
Bought, twelve months
$585
1 purchases by 1 insider; officers and directors $585
Sold, twelve months
$905K
4 sales by 2 insiders; officers and directors $905K

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 2, 2026Godbout SeanChief Accounting Officeroption exercise27$0.00—1,467Oct 5, 2026
Oct 2, 2026Godbout SeanChief Accounting Officertax withholding8$219.88$2K1,459Oct 5, 2026
Aug 4, 2026Minor LloydDirectoropen-market sale10b5-1593$200.96$119K2,689Aug 5, 2026
Aug 3, 2026Minor LloydDirectoropen-market sale10b5-1593$203.34$121K3,282Aug 5, 2026
Jun 9, 2026Hawkins William ADirectoraward1,505$0.00—10,365Jun 11, 2026
Jun 9, 2026Sherwin Stephen ADirectoraward1,505$0.00—15,193Jun 11, 2026
Jun 9, 2026Rowinsky Eric KDirectoraward1,505$0.00—25,844Jun 11, 2026
Jun 9, 2026Mantas Jesus BDirectoraward1,505$0.00—11,263Jun 11, 2026
Jun 9, 2026Langer SusanDirectoraward1,505$0.00—6,634Jun 11, 2026
Jun 9, 2026Patolawala Monish DDirectoraward1,505$0.00—5,215Jun 11, 2026
Jun 9, 2026Pangalos Menelas NDirectoroption exercise2,370$0.00—2,370Jun 11, 2026
Jun 9, 2026Pangalos Menelas NDirectoraward1,505$0.00—3,875Jun 11, 2026
Jun 9, 2026Minor LloydDirectoraward1,505$0.00—3,875Jun 11, 2026
Jun 9, 2026Freire Maria CDirectoraward2,005$0.00—8,820Jun 11, 2026
May 1, 2026Keeney AdamHead of Corporate Developmentoption exercise939$0.00—6,820May 5, 2026
May 1, 2026Keeney AdamHead of Corporate Developmenttax withholding455$187.06$85K6,365May 5, 2026
Apr 1, 2026Godbout SeanChief Accounting Officeroption exercise181$0.00—1,396Apr 3, 2026
Apr 1, 2026Godbout SeanChief Accounting Officertax withholding54$183.78$10K1,342Apr 3, 2026
Feb 12, 2026Murphy NicoleHead of Pharm Ops and Techopen-market buy3$195.04$58519,611Feb 17, 2026
Feb 9, 2026Singhal PriyaHead of Developmentopen-market sale10b5-12,660$199.83$532K8,043Feb 10, 2026
Feb 6, 2026Viehbacher ChristopherPresident and CEO, Directoroption exercise9,008$0.00—25,451Feb 10, 2026
Feb 6, 2026Viehbacher ChristopherPresident and CEO, Directortax withholding6,624$201.18$1M29,924Feb 10, 2026
Feb 6, 2026Viehbacher ChristopherPresident and CEO, Directoroption exercise15,453$0.00—36,548Feb 10, 2026
Feb 6, 2026Viehbacher ChristopherPresident and CEO, Directortax withholding4,356$201.18$876K21,095Feb 10, 2026
Feb 6, 2026Singhal PriyaHead of Developmentoption exercise2,217$0.00—8,488Feb 10, 2026

Full insider history for Biogen Inc. Common Stock, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
BIOGEN INC., CIK 875045 on EDGAR
Extract generated
October 29, 2026
Withheld
2 line-years whose four quarters do not sum to the filed year: buybacks FY2013, other income FY2021
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: Revenues
Cost of revenue: CostOfGoodsAndServicesSold, CostOfRevenue
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense, OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent, MarketableSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAndAmortization, DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated October 29, 2026.

JSON file
/data/financials/BIIB.json